Abstract:In oral delivery of biomacromolecules, ligand-modified nanoparticles (NPs) have emerged as a promising tool to improve the epithelial uptake of the loaded protein/peptide. Unfortunately, the stability and the transport mechanisms of the biotherapeutics during the intracellular transportation still remained unclear, leading to the poor transepithelial efficiency. Additionally, developing novel approaches to simultaneously monitor the payload bioactivity during the transport processes is veritably benefit for keeping their bioactivity. In the present study, EGP peptide (KRKKKGKGLGKKRDPCLRKYK), a ligand with high affinity to heparan sulfate proteoglycans (HSPGs), was found remarkably increasing the cellular uptake (4.5-fold) and also surprisingly achieving high transcytosis efficiency (4.2-fold) of poly(lactide- co-glycolide) NPs on Caco-2 cell monolayer. Compared with unmodified NPs (C NPs), EGP modified NPs (EGP NPs) exhibited more desirable colloidal stability within epithelia. In the subsequent study, the bioactivity of encapsulated insulin during the cellular transportation was innovatively monitored by a glucose consumption assay. Inspiringly, EGP NPs could mostly retain the bioactivity of loaded insulin whereas insulin from INS-C NPs was significantly degraded. Then the detailed mechanism study revealed that the binding of EGP to HSPGs played a vital role on NP transportation. Unlike C NPs being delivered in the endo/lysosomal pathway, EGP NPs were involved in caveolae-mediated transport, which contributes to the efficient avoidance of the lysosomal entrapment and sequentially facilitates the direct apical-to-basolateral transcytosis. The enhanced absorption of EGP NPs was confirmed in in situ intestinal loop models. Most importantly, oral administrated INS-EGP NPs generated a strong hypoglycemic response on diabetic rats with 10.2-fold and 2.6-fold increase in bioavailability compared with free insulin and INS-C NPs, respectively. The work provided an innovative strategy to monitor the payload bioactivity during the transport processes and proposed a novel aspect to increase oral bioavailability of biomacromolecules via improving payload stability and regulating the transcytosis pathway of nanocarriers.

Core-shell Nanosystems Designed for Effective Oral Delivery of Polypeptide Drugs

Oral Delivery of Decanoic Acid Conjugated Plant Protein Shell Incorporating Hybrid Nanosystem Leverage Intestinal Absorption of Polyphenols.

Nanoemulsion-Templated Shell-Crosslinked Nanocapsules As Drug Delivery Systems

l-Arginine/l-lysine functionalized chitosan-casein core-shell and pH-responsive nanoparticles: fabrication, characterization and bioavailability enhancement of hydrophobic and hydrophilic bioactive compounds.

A Novel Oral Protein-Drug Delivery System with Bilayer Shell-Core Structure

Mucus- and pH-mediated controlled release of core-shell chitosan nanoparticles in the gastrointestinal tract for diabetes treatment

Single-Cell Oral Delivery Platform for Enhanced Acid Resistance and Intestinal Adhesion

N-Acetyl-l-cysteine/l-Cysteine-Functionalized Chitosan−β-Lactoglobulin Self-Assembly Nanoparticles: A Promising Way for Oral Delivery of Hydrophilic and Hydrophobic Bioactive Compounds

Design and Intestinal Mucus Penetration Mechanism of Core-Shell Nanocomplex

Enhanced Oral Delivery of Protein Drugs Using Zwitterion-Functionalized Nanoparticles to Overcome Both the Diffusion and Absorption Barriers

Uniform Core-Shell Nanoparticles with Thiolated Hyaluronic Acid Coating to Enhance Oral Delivery of Insulin

Multifunctional Nanoparticles Enable Efficient Oral Delivery of Biomacromolecules Via Improving Payload Stability and Regulating the Transcytosis Pathway.

Semi-elastic Core-Shell Nanoparticles Enhanced the Oral Bioavailability of Peptide Drugs

Nanoparticles Incorporated in Bilaminated Films: A Smart Drug Delivery System for Oral Formulations

Improving the Oral Delivery Efficiency of Anticancer Drugs by Chitosan Coated Polycaprolactone-Grafted Hyaluronic Acid Nanoparticles.

Progress and prospects of polysaccharide-based nanocarriers for oral delivery of proteins/peptides

Fabrication of nanostructured multi-unit vehicle for intestinal-specific delivery and controlled release of peptide

Core-shell Stability of Nanoparticles Plays an Important Role for Overcoming the Intestinal Mucus and Epithelium Barrier.

Nanoparticles: Oral Delivery for Protein and Peptide Drugs

Multilayer Sodium Alginate Beads with Porous Core Containing Chitosan Based Nanoparticles for Oral Delivery of Anticancer Drug

Oral Delivery of Protein Drugs via Lysine Polymer‐Based Nanoparticle Platforms